Scholar Rock Holding Corporation received FDA approval for ISEMBYLD, a new treatment for spinal muscular atrophy (SMA) targeting muscle function. This approval marks a significant advancement as the drug is the first muscle-targeted therapy for SMA, usable alongside existing treatments for both children and adults. Following this milestone, Citigroup maintained a "Buy" rating on Scholar Rock and raised its price target from $60 to $74, reflecting strong confidence in the company's growth prospects. Scholar Rock's stock is actively traded with a market cap of about $6.64 billion, indicating solid investor interest.
Scholar Rock's recent FDA approval and Citigroup upgrade provide context for the healthcare sector's performance on Pluang as of Sep 14, 2026 20:12 WIB. Of 91 priced health-sector US stocks tradable on Pluang, 53 rose and 28 fell today. Notable movers include CTXR at USD 0.60 with a 3.75% increase, MDT at USD 94.25 up 3.62%, and NVS at USD 141.49 rising 3.16%.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
